A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

The drug, Mazdutide, is the world's first and currently only GCG/GLP-1 dual receptor agonist targeting both weight loss and ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...

By Dennis Thompson HealthDay ReporterWEDNESDAY, May 28, 2025 (HealthDay News) — Popular GLP-1 weight loss drugs like Ozempic ...

SYNT-101 introduces an innovative method for weight loss by temporarily redirecting nutrient absorption in the small ...

Most current drugs for obesity and diabetes, like liraglutide, target a hormone receptor known as GLP-1. These medications ...

American teens are increasingly turning to the weight-loss drug Wegovy, as more families and their doctors gain confidence in ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...